MedDataX Logo

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT ID: NCT03131453

Last Updated: 2021-08-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

1145 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-03

Study Completion Date

2020-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511

Alzheimers Disease
TERMINATED PHASE2/PHASE3

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

NCT02576639

Alzheimer's Disease
COMPLETED PHASE2

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

NCT01827982

Healthy
COMPLETED PHASE1

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

NCT02260674

Alzheimer's Disease
COMPLETED PHASE2

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

NCT02406027

Alzheimer Disease
TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial was a randomized, double-blind, placebo-controlled, parallel group, adaptive design with variable treatment duration planned in cognitively unimpaired participants aged 60 to 75 years, with at least one apolipoprotein E allele (APOE4), (homozygotes (HMs) or heterozygotes (HTs)) and, if HTs, with evidence of elevated brain amyloid. The participants were randomized to either CNP520 50 mg, CNP520 15 mg or placebo a 2:1:2 ratio and was stratified based on amyloid status. The planned treatment period of 5 to 8 years was not achieved due to early study termination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimers Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CNP520 50 mg

50 mg capsule taken orally once daily

Group Type EXPERIMENTAL

CNP520 50mg

Intervention Type DRUG

50 mg capsule

CNP520 15 mg

15 mg capsule taken orally once daily

Group Type EXPERIMENTAL

CNP520 15mg

Intervention Type DRUG

15 mg capsule

Placebo

Matching placebo to 15 and 50 mg CNP520 taken orally once daily

Group Type PLACEBO_COMPARATOR

Matching placebo

Intervention Type OTHER

Matching placebo for 15 and 50 mg capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CNP520 50mg

50 mg capsule

Intervention Type DRUG

CNP520 15mg

15 mg capsule

Intervention Type DRUG

Matching placebo

Matching placebo for 15 and 50 mg capsules

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* consent to receive disclosure of their risk estimates to develop clinical symptoms of AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain amyloid.
* Male or female, age 60 to 75 years inclusive. Females must be considered post-menopausal and not of child bearing potential
* Cognitively unimpaired as evaluated by memory tests performed at screening.
* Participant's willingness to have a study partner.
* Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as measured by CSF Abeta or amyloid PET imaging).

Exclusion Criteria

* Any disability that could have prevented the participants from completing all study requirements. -
* Current medical or neurological condition that could have impacted cognition or performance on cognitive assessments.
* Advanced, severe progressive or unstable disease that could have interfered with the safety, tolerability and study assessments, or put the participant at special risk.
* History of malignancy of any organ system, treated or untreated, within the past 60 months.
* Indication for, or current treatment with ChEIs and/or another AD treatment (e.g. memantine).
* Contraindication or intolerance to MRI.
* Brain MRI results showing findings unrelated to AD that, in the opinion of the Investigator might be a leading cause to future cognitive decline, could have posed a risk to the participant, or could have prevented a satisfactory MRI assessment for safety monitoring.
* Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.
* A positive drug screen at Screening, if, in the Investigator's opinion, was is due to drug abuse.
* Significantly abnormal laboratory results at Screening, not as a result of a temporary condition.
* Current clinically significant ECG findings.
* Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism, vitiligo) or active / history of chronic urticaria in the past year.
Minimum Eligible Age

60 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role collaborator

Banner Alzheimer's Institute

OTHER

Sponsor Role collaborator

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner Alzheimer's Institute, 901 East Willetta Street

Phoenix, Arizona, United States

Site Status

Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Building B

Sun City, Arizona, United States

Site Status

Novartis Investigative Site

Tucson, Arizona, United States

Site Status

ATP Clinical Research Inc, 3151 Airway Avenue T 3

Costa Mesa, California, United States

Site Status

Irvine Center for Clinical Res, 2515 McCabe Way

Irvine, California, United States

Site Status

Torrance Clinical Research Institute, 25043 Narbonne Avenue

Lomita, California, United States

Site Status

Novartis Investigative Site

Oxnard, California, United States

Site Status

Novartis Investigative Site

Palo Alto, California, United States

Site Status

Novartis Investigative Site

San Diego, California, United States

Site Status

Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130

Santa Ana, California, United States

Site Status

Novartis Investigative Site

Sebastopol, California, United States

Site Status

Novartis Investigative Site

Sherman Oaks, California, United States

Site Status

Mountain Neurological Research, 350 Market Street, Suite 316

Basalt, Colorado, United States

Site Status

Colorado Springs Neurological, 2312 North Nevada Avenue, Suite 100

Colorado Springs, Colorado, United States

Site Status

Denver Neurological Clinic, 950 E Harvard Ave

Denver, Colorado, United States

Site Status

Yale University, One Church Street, Suite 600

New Haven, Connecticut, United States

Site Status

Novartis Investigative Site

Stamford, Connecticut, United States

Site Status

Novartis Investigative Site

Washington D.C., District of Columbia, United States

Site Status

Novartis Investigative Site

Atlantis, Florida, United States

Site Status

Quantum Laboratories

Deerfield Beach, Florida, United States

Site Status

Brain Matters Research, Inc., 800 NW 17th Avenue

Delray Beach, Florida, United States

Site Status

Infinity Clinical Research LLC, 4925 Sheridan Street, Suite 200

Hollywood, Florida, United States

Site Status

Alzheimer's Research and Treatment Center, 5065 State Road 7, Suite 102

Lake Worth, Florida, United States

Site Status

Meridien Research, 2300 Maitland center, Pkwy Ste 230

Maitland, Florida, United States

Site Status

Novartis Investigative Site

Melbourne, Florida, United States

Site Status

Novartis Investigative Site

Merritt Island, Florida, United States

Site Status

Novartis Investigative Site

Miami, Florida, United States

Site Status

Novartis Investigative Site

Miami, Florida, United States

Site Status

New Horizon Research Center, 11880 SW 40 St., Suite 405

Miami, Florida, United States

Site Status

Miami-Dade Medical Research, 8955 SW 87 CT, Suite 112

Miami, Florida, United States

Site Status

Novartis Investigative Site

Miami Beach, Florida, United States

Site Status

Compass Research, LLC,100 West Gore Street, Suite 202

Orlando, Florida, United States

Site Status

Novartis Investigative Site

Orlando, Florida, United States

Site Status

Novartis Investigative Site

Ormond Beach, Florida, United States

Site Status

Novartis Investigative Site

Palm Beach Gardens, Florida, United States

Site Status

Novartis Investigative Site

Port Orange, Florida, United States

Site Status

Roskamp Institute, Inc., 2040 Whitfield Avenue

Sarasota, Florida, United States

Site Status

Novartis Investigative Site

Tallahassee, Florida, United States

Site Status

Novartis Investigative Site

Tampa, Florida, United States

Site Status

Novartis Investigative Site

West Palm Beach, Florida, United States

Site Status

Novartis Investigative Site

Atlanta, Georgia, United States

Site Status

Novartis Investigative Site

Columbus, Georgia, United States

Site Status

Novartis Investigative Site

Decatur, Georgia, United States

Site Status

Hawaii Pacific Neuroscience, 2230 Liliha st 104

Honolulu, Hawaii, United States

Site Status

Advanced Clinical Research, 2950 E Magic View Dr, Suite 182

Meridian, Idaho, United States

Site Status

Novartis Investigative Site

Chicago, Illinois, United States

Site Status

Novartis Investigative Site

Chicago, Illinois, United States

Site Status

Alexian Brothers Neuroscience, 800 Biesterfield Rd, Neuroscience Institute Brock

Elk Grove Village, Illinois, United States

Site Status

Novartis Investigative Site

Indianapolis, Indiana, United States

Site Status

Novartis Investigative Site

Fairway, Kansas, United States

Site Status

Novartis Investigative Site

Wichita, Kansas, United States

Site Status

Novartis Investigative Site

Wichita, Kansas, United States

Site Status

Novartis Investigative Site

Lexington, Kentucky, United States

Site Status

Novartis Investigative Site

Bangor, Maine, United States

Site Status

Novartis Investigative Site

Boston, Massachusetts, United States

Site Status

Novartis Investigative Site

Boston, Massachusetts, United States

Site Status

QUEST Research Institute, 28595 Orchard Lake Road, Suite 301

Farmington Hills, Michigan, United States

Site Status

Novartis Investigative Site

Kalamazoo, Michigan, United States

Site Status

Novartis Investigative Site

Rochester, Minnesota, United States

Site Status

Hattiesburg Clinic, 415 South 28th Avenue

Hattiesburg, Mississippi, United States

Site Status

Novartis Investigative Site

St Louis, Missouri, United States

Site Status

Novartis Investigative Site

Omaha, Nebraska, United States

Site Status

Novartis Investigative Site

West Long Branch, New Jersey, United States

Site Status

Albuquerque Neuroscience, 101 Hospital Loop ne, 209 209

Albuquerque, New Mexico, United States

Site Status

Novartis Investigative Site

Brooklyn, New York, United States

Site Status

Novartis Investigative Site

East Syracuse, New York, United States

Site Status

Novartis Investigative Site

Latham, New York, United States

Site Status

NYU Langone Medical Center, 145 East 32nd Street, 2nd Floor, Room 226

New York, New York, United States

Site Status

Novartis Investigative Site

Orangeburg, New York, United States

Site Status

Novartis Investigative Site

Rochester, New York, United States

Site Status

ANI Neurology, PLLC dba Alzhe, 7809 Sardis Road

Charlotte, North Carolina, United States

Site Status

Novartis Investigative Site

Durham, North Carolina, United States

Site Status

Novartis Investigative Site

Greensboro, North Carolina, United States

Site Status

Novartis Investigative Site

Cincinnati, Ohio, United States

Site Status

Novartis Investigative Site

Oklahoma City, Oklahoma, United States

Site Status

Tulsa Clinical Research LLC, 1705 E 19th ST., STE 406/408

Tulsa, Oklahoma, United States

Site Status

Summit Research Network, 2701 NW Vaughn St, Suite 350

Portland, Oregon, United States

Site Status

Novartis Investigative Site

Portland, Oregon, United States

Site Status

Novartis Investigative Site

Jenkintown, Pennsylvania, United States

Site Status

Novartis Investigative Site

Philadelphia, Pennsylvania, United States

Site Status

Abington Neurological Associate Ltd., 2325 Maryland Road, Suite 100

Willow Grove, Pennsylvania, United States

Site Status

Rhode Island Hospital and Memory Research Institute, 1018 Waterman Ave

East Providence, Rhode Island, United States

Site Status

Butler Hospital, 345 Blackstone Blvd.

Providence, Rhode Island, United States

Site Status

Roper Hospital, 316 Calhoun Street 5th Floor

Charleston, South Carolina, United States

Site Status

Novartis Investigative Site

Knoxville, Tennessee, United States

Site Status

Novartis Investigative Site

Memphis, Tennessee, United States

Site Status

Novartis Investigative Site

Nashville, Tennessee, United States

Site Status

Novartis Investigative Site

Austin, Texas, United States

Site Status

Novartis Investigative Site

Dallas, Texas, United States

Site Status

Novartis Investigative Site

Houston, Texas, United States

Site Status

Novartis Investigative Site

Houston, Texas, United States

Site Status

Novartis Investigative Site

San Antonio, Texas, United States

Site Status

Novartis Investigative Site

Bennington, Vermont, United States

Site Status

Novartis Investigative Site

Tacoma, Washington, United States

Site Status

Novartis Investigative Site

Milwaukee, Wisconsin, United States

Site Status

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Darlinghurst, New South Wales, Australia

Site Status

Novartis Investigative Site

Heidelberg West, Victoria, Australia

Site Status

Novartis Investigative Site

Nedlands, Western Australia, Australia

Site Status

Novartis Investigative Site

Ghent, , Belgium

Site Status

Novartis Investigative Site

Leuven, , Belgium

Site Status

Novartis Investigative Site

Kelowna, British Columbia, Canada

Site Status

Novartis Investigative Site

Kentville, Nova Scota, Canada

Site Status

Novartis Investigative Site

Halifax, Nova Scotia, Canada

Site Status

Novartis Investigative Site

Ottawa, Ontario, Canada

Site Status

Toronto Memory Program, 1 Valleybrook Drive Suite 400

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Gatineau, Quebec, Canada

Site Status

Novartis Investigative Site

Greenfield Park, Quebec, Canada

Site Status

Novartis Investigative Site

Québec, Quebec, Canada

Site Status

Novartis Investigative Site

Santiago, , Chile

Site Status

Novartis Investigative Site

Santiago, , Chile

Site Status

Novartis Investigative Site

Shanghai, Shanghai Municipality, China

Site Status

Novartis Investigative Site

Beijing, , China

Site Status

Novartis Investigative Site

Guangdong, , China

Site Status

Novartis Investigative Site

Kuopio, , Finland

Site Status

Novartis Investigative Site

Turku, , Finland

Site Status

Novartis Investigative Site

Strasbourg, Cedex, France

Site Status

Novartis Investigative Site

Lille, , France

Site Status

Novartis Investigative Site

Paris, , France

Site Status

Novartis Investigative Site

Rouen, , France

Site Status

Novartis Investigative Site

Toulouse, , France

Site Status

Novartis Investigative Site

Villeurbanne, , France

Site Status

Novartis Investigative Site

Bayreuth, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Cologne, , Germany

Site Status

Novartis Investigative Site

Leipzig, , Germany

Site Status

Novartis Investigative Site

Mannheim, , Germany

Site Status

Novartis Investigative Site

Siegen, , Germany

Site Status

Novartis Investigative Site

Kopavogur, , Iceland

Site Status

Novartis Investigative Site

Ashkelon, , Israel

Site Status

Novartis Investigative Site

Haifa, , Israel

Site Status

Novartis Investigative Site

Petah Tikva, , Israel

Site Status

Novartis Investigative Site

Ramat Gan, , Israel

Site Status

Novartis Investigative Site

Tel Aviv, , Israel

Site Status

Novartis Investigative Site

Brescia, BS, Italy

Site Status

Novartis Investigative Site

Rome, Lazio, Italy

Site Status

Novartis Investigative Site

Monza, MB, Italy

Site Status

Novartis Investigative Site

Milan, , Italy

Site Status

Novartis Investigative Site

Tōon, Ehime, Japan

Site Status

Novartis Investigative Site

Fukuoka, Fukuoka, Japan

Site Status

Novartis Investigative Site

Yokohama, Kanagawa, Japan

Site Status

Novartis Investigative Site

Suita, Osaka, Japan

Site Status

Novartis Investigative Site

Bunkyo Ku, Tokyo, Japan

Site Status

Novartis Investigative Site

Bunkyo Ku, Tokyo, Japan

Site Status

Novartis Investigative Site

Kodaira, Tokyo, Japan

Site Status

Novartis Investigative Site

Shinjuku-ku, Tokyo, Japan

Site Status

Novartis Investigative Site

Chiba, , Japan

Site Status

Novartis Investigative Site

Osaka, , Japan

Site Status

Novartis Investigative Site

Mexico City, Mexico CP, Mexico

Site Status

Novartis Investigative Site

Monterrey, Nuevo León, Mexico

Site Status

Novartis Investigative Site

Culiacán, Sinaloa, Mexico

Site Status

Novartis Investigative Site

's-Hertogenbosch, North Brabant, Netherlands

Site Status

Novartis Investigative Site

Amsterdam, , Netherlands

Site Status

Novartis Investigative Site

Torres Vedras, Lisbon District, Portugal

Site Status

Novartis Investigative Site

Coimbra, , Portugal

Site Status

Novartis Investigative Site

Lisbon, , Portugal

Site Status

Novartis Investigative Site

Matosinhos Municipality, , Portugal

Site Status

Inspira Clinical Research, Ave Hostos 405

San Juan, , Puerto Rico

Site Status

Novartis Investigative Site

Singapore, , Singapore

Site Status

Novartis Investigative Site

Rosebank, Johannesburg, South Africa

Site Status

Novartis Investigative Site

Cape Town, Western Cape, South Africa

Site Status

Novartis Investigative Site

George, ZAF, South Africa

Site Status

Novartis Investigative Site

Suwon, Gyeonggi-do, South Korea

Site Status

Novartis Investigative Site

Busan, , South Korea

Site Status

Novartis Investigative Site

Incheon, , South Korea

Site Status

Novartis Investigative Site

Seoul, , South Korea

Site Status

Novartis Investigative Site

Seoul, , South Korea

Site Status

Novartis Investigative Site

Terrassa, Barcelona, Spain

Site Status

Novartis Investigative Site

Pozuelo de Alarcón, Madrid, Spain

Site Status

Novartis Investigative Site

Barcelona, , Spain

Site Status

Novartis Investigative Site

Barcelona, , Spain

Site Status

Novartis Investigative Site

Donostia / San Sebastian, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Basel, CH, Switzerland

Site Status

Novartis Investigative Site

Geneva, , Switzerland

Site Status

Novartis Investigative Site

Lausanne, , Switzerland

Site Status

Novartis Investigative Site

Kaoshiung, , Taiwan

Site Status

Novartis Investigative Site

New Taipei City, , Taiwan

Site Status

Novartis Investigative Site

Taipei, , Taiwan

Site Status

Novartis Investigative Site

Exeter, Devon, United Kingdom

Site Status

Novartis Investigative Site

Plymouth, Devon, United Kingdom

Site Status

Novartis Investigative Site

London, GBR, United Kingdom

Site Status

Novartis Investigative Site

Guildford, Surrey, United Kingdom

Site Status

Novartis Investigative Site

Avon, , United Kingdom

Site Status

Novartis Investigative Site

Birmingham, , United Kingdom

Site Status

Novartis Investigative Site

Bristol, , United Kingdom

Site Status

Novartis Investigative Site

Dundee, , United Kingdom

Site Status

Novartis Investigative Site

Glasgow, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Canada Chile China Finland France Germany Iceland Israel Italy Japan Mexico Netherlands Portugal Puerto Rico Singapore South Africa South Korea Spain Switzerland Taiwan United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-002976-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CCNP520A2202J

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727 RECRUITING PHASE1
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
NCT06402838 ACTIVE_NOT_RECRUITING PHASE2
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
NCT05256134 TERMINATED PHASE3
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
NCT03114657 TERMINATED PHASE3
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
NCT02820896 COMPLETED PHASE1
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
NCT04592874 COMPLETED PHASE2
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
NCT03721705 COMPLETED PHASE3
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
NCT00810147 COMPLETED PHASE2
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
NCT02670083 TERMINATED PHASE3
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants
NCT01887535 COMPLETED PHASE1
Nasal Protollin in Early Symptomatic Alzheimer's Disease
NCT07187141 COMPLETED PHASE1
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
NCT04251182 COMPLETED PHASE2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
NCT01548287 COMPLETED PHASE2
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
NCT07221344 RECRUITING PHASE1/PHASE2
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
NCT03444870 TERMINATED PHASE3
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
NCT02322021 TERMINATED PHASE2
Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)
NCT01181310 COMPLETED PHASE1
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
NCT01397578 COMPLETED PHASE2
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
NCT04795466 TERMINATED PHASE2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451 NOT_YET_RECRUITING PHASE1
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578 RECRUITING PHASE3
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
NCT02648672 COMPLETED PHASE1
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
NCT03491150 TERMINATED PHASE3
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
NCT02840279 COMPLETED PHASE1